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ABSTRACT
Objective The optimal target heart rate in patients with 
prevalent atrial fibrillation (AF) is not well defined. The aim 
of this study was to analyse the associations between 
heart rate and adverse outcomes in a large contemporary 
cohort of patients with prevalent AF.
Methods From two prospective cohort studies, we 
included stable AF outpatients who were in AF on the 
baseline ECG. The main outcome events assessed during 
prospective follow- up were heart failure hospitalisation, 
stroke or systemic embolism and death. The associations 
between heart rate and adverse outcomes were evaluated 
using multivariable Cox regression models.
Results The study population consisted of 1679 patients 
who had prevalent AF at baseline. Mean age was 74 
years, and 24.6% were women. The mean heart rate on 
the baseline ECG was 78 (±19) beats per minute (bpm). 
The median follow- up was 3.9 years (IQR 2.2–5.0). Heart 
rate was not significantly associated with heart failure 
hospitalisation (adjusted HR (aHR) per 10 bpm increase, 
1.00, 95% CI 0.94 to 1.07, p=0.95), stroke or systemic 
embolism (aHR 0.95, 95% CI 0.84 to 1.07, p=0.38) or 
death (aHR 1.02, 95% CI 0.95 to 1.09, p=0.66). There was 
no evidence of a threshold effect for heart rates <60 bpm 
or >100 bpm.
Conclusions In this large contemporary cohort of 
outpatients with prevalent AF, we found no association 
between heart rate and adverse outcome events. These 
data are in line with recommendations that strict heart 
rate control is not needed in otherwise stable outpatients 
with AF.
INTRODUCTION
Atrial fibrillation (AF) is the most common 
sustained cardiac arrhythmia in the general 
population, and its prevalence is rapidly 
increasing.1 AF is associated with an increased 
risk of heart failure, stroke and death.2–4
Treatment options for AF patients with 
prevalent AF on the ECG include both 
rhythm and rate control, as neither has been 
shown to be superior for patients eligible for 
both options.5–8 While an increased heart 
rate has been consistently associated with 
mortality and morbidity in sinus rhythm 
patients,8–11 much less information is avail-
able on the prognostic value of heart rate in 
patients with prevalent AF. In the relatively 
small Rate Control Efficacy in Permanent 
Atrial Fibrillation: a Comparison between 
Lenient versus Strict Rate Control II (RACE- 
II) trial, lenient rate control was not infe-
rior to strict rate control for preventing the 
primary composite outcome of cardiovas-
cular death, hospitalisation for heart failure, 
stroke, systemic embolism, bleeding and life- 
threatening arrhythmic events in patients 
with permanent AF.6 Pooled data from RACE 
and AFFIRM did not show a significant differ-
ence in the primary endpoint (composite of 
Key questions
What is already known about this subject?
 ► Heart rate control is considered first- line therapy 
option in patients with atrial fibrillation (AF), howev-
er, for the majority of stable outpatients with AF the 
optimal heart rate target is still unclear.
What does this study add?
 ► In this large contemporary cohort of patients with 
prevalent AF, heart rate assessed using a 10 s rest-
ing ECG was not associated with heart failure hos-
pitalisation, stroke or systemic embolism and death. 
These data reinforce current recommendations that 
strict heart rate control is not needed to guide man-
agement in otherwise stable outpatients with AF.
How might this impact on clinical practice?
 ► In daily clinical practice, a large proportion of pa-
tients with AF are stable and asymptomatic. Our 
findings derived from a large community- based 
cohort will help patients and clinicians to guide de-
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mortality, cardiovascular hospitalisation and myocardial 
infarction) between a more strict (target heart rate <80 
beats per minute (bpm)) vs a more lenient (heart rate 
<100 bpm) rate control.7 In another analysis, heart rate 
during AF was not associated with mortality, in contrast 
to heart rate during sinus rhythm.8
Current guidelines propose an initial resting heart rate 
target of <110 bpm mainly to improve haemodynamic 
stability, reduce symptoms and preserve left ventricular 
function.12 However, for the large group of AF patients 
who are haemodynamically stable and mostly asymptom-
atic, more data are needed to determine the optimal 
heart rate target.
We, therefore, conducted the current analysis to assess 
the associations between heart rate and several adverse 
outcome events in a large cohort of contemporary outpa-




The study population was derived from two similar and 
ongoing prospective cohort studies: Swiss AF (Swiss- AF, 
n=2415) and Basel AF (BEAT- AF, n=1546) cohort study. 
We excluded subjects who were not in AF or atrial flutter 
at the time of the baseline examination (n=2207) or 
subjects with missing data on heart rhythm (n=27) or 
other covariates (n=48). The final study population 
consisted of 1679 individuals with AF at the baseline 
examination.
Written informed consent has been obtained from the 
participants (or their guardians).
Methodology and data collection in Swiss- AF and 
BEAT- AF were very similar and have been previously 
described in detail.13–16 Both studies have recruited from 
multiple sites in Switzerland, with enrolment during 
2010–2014 for BEAT- AF and 2014–2017 for Swiss- AF. In 
both cohorts, patients had to be 65 years or older and 
have established, previously documented AF. A conve-
nience sample of patients aged 45–64 years was enrolled 
in both cohorts to evaluate the effects of AF on the active 
workforce. Patient with an acute illness in the past 4 weeks 
could only be enrolled after clinical stabilisation. Patients 
with transient AF in connection with an acute illness or 
surgery were excluded. Patients enrolled in BEAT- AF 
could not participate in Swiss- AF.
Baseline measurements and follow-up assessments
Baseline examination included the same case report form 
in both cohorts. Heart rhythm and rate were obtained 
from a standard resting 12- lead ECG (BEAT- AF) or 16- lead 
ECG (Swiss- AF) during a 10 s registration.15 Weight (kg) 
and height (metre (m)) were directly measured. Body 
mass index (BMI) was calculated as kg/m2. Smoking status 
was categorised into current smokers, former smokers 
and never smokers. Regular physical activity was defined 
as physical exercise on a regular basis (yes/no). Alcohol 
consumption was calculated as number of standard unit 
drinks per day. AF was classified according to the 2010 
guidelines of the European Society of Cardiology into 
paroxysmal (self- terminating), persistent (lasting ≥7 days 
or requiring termination by electrical or pharmacolog-
ical cardioversion) or permanent AF (accepted by patient 
and physician).17 Antiarrhythmic drugs were categorised 
according to the Vaughan- Williams classification: class 1 
(sodium- channel blocker), class 2 (beta- blockers), class 
3 (amiodarone, sotalol and dronedarone) and class 4 
(non- dihydropyridine calcium- channel blocker). History 
of coronary artery disease (CAD) was defined as a history 
of myocardial infarction, percutaneous coronary angio-
plasty or coronary by- pass graft surgery. After an in- person 
baseline visit in both cohorts, follow- up was conducted 
annually by mail and phone interviews in BEAT- AF, and 
by in- person visits in Swiss- AF.
Clinical outcome events
Both cohorts used the same definitions for all clinical 
adverse outcome events. All events were validated by 
two physicians in a standardised way, on the basis of all 
available information. In case of discordant assessments, 
a third reviewer physician was consulted. Incident heart 
failure hospitalisation was defined as a hospitalisation for 
congestive heart failure that was associated with at least 
one overnight stay, or a congestive heart failure exacerba-
tion that led to an extension of an existing hospitalisation. 
Stroke was defined as an acute focal neurological deficit 
of vascular origin, confirmed by imaging (CT or MRI) or 
autopsy, and systemic embolism was defined as evidence 
of abrupt occlusion of a systemic artery consistent with 
an embolic event. Detailed outcome event definitions are 
provided in online supplemental table 1.
Patient and public involvement
Patients and public were not involved in the design, or 
conduct, or reporting, or dissemination plans of this 
research.
Statistical analysis
Baseline characteristics are presented across quartiles 
of heart rate. Differences across quartiles were analysed 
using analysis of variance for normally distributed contin-
uous variables, Kruskal- Wallis tests for non- normally 
distributed continuous variables and χ2 tests for categor-
ical variables.
Follow- up analyses to evaluate the associations between 
heart rate and clinical outcome events were performed 
using Cox regression models adjusted for two prespecified 
set of covariates. In model 1, we adjusted for age and sex. 
In model 2, we additionally adjusted for BMI, history of 
hypertension, history of diabetes mellitus, history of CAD, 
history of stroke or transient ischaemic attack, history of 
heart failure, type of AF (paroxysmal and persistent vs 
permanent), smoking status, alcohol consumption, phys-
ical activity, use of antiarrhythmic medication according 
to the Vaughan Williams classification, digoxin and oral 
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anticoagulation. The associations between heart rate 
and outcome events were analysed per 10 bpm as well as 
by prespecified categories for low heart rate defined as 
<60 bpm, or high heart rate defined as ≥100 bpm.
The shape of the association of heart rate with the 
heart failure hospitalisation, stroke and mortality was 
further assessed by including a quadratic term into model 
2. Interaction between heart rate and sex or history of 
heart failure at baseline was assessed by including a multi-
plicative interaction parameter in model 2. Finally, we 
further assessed the association between heart rate and 
heart failure hospitalisation and stroke or systemic embo-
lism after accounting for the competing risk of mortality 
using competing risk regression as described by Fine 
and Gray.18 The proportional hazards assumption was 
assessed visually using Nelson- Aalen plots and found to 
be valid for all models. A two- sided p<0.05 was considered 
statistically significant. All analyses were performed with 
Stata SE V. 15.1. Data are not available.
RESULTS
The mean age of the study population (n=1679) was 
74 years (SD 9 years), 24.6% were women, and 51.4% 
had permanent AF. The mean heart rate at the time of 
enrollment was 78 bpm (SD 19 bpm, range 31–160 bpm); 
9.7% (n=162) had a heart rate <60 bpm, and 12.0% 
(n=201) a heart rate >100 bpm. The median follow- up 
duration was 3.9 years (IQR 2.2–5.0). Baseline character-
istics stratified by quartiles of heart rate are reported in 
table 1.
Heart rate and heart failure hospitalisation
During the follow- up, there were 301 heart failure hospi-
talisations, corresponding to an incidence rate of 47.4 
(95% CI 42.3 to 53.0) per 1000 person- years. There 
was no significant association between heart rate and 
heart failure hospitalisation using either Cox regression 
models or competing risks regression (tables 2 and 3). 
We found no evidence of a nonlinear association (p for 
quadratic term=0.47), nor was there a significant asso-
ciation between heart rates <60 or ≥100 bpm with heart 
failure hospitalisation (table 2). There was no evidence 
of interaction between heart rate and either sex (p for 
interaction=0.99) or history of heart failure (p for inter-
action=0.22).
Heart rate and stroke or systemic embolism
There were 96 stroke or systemic embolism events during 
follow- up, corresponding to an incidence rate of 14.4 
Table 1 Baseline characteristics by quartiles of baseline heart rate
Characteristics (n=1679) Quartile 1 (n=395) Quartile 2 (n=442) Quartile 3 (n=395) Quartile 4 (n=447) P value
Heart rate range, bpm 31–64 65–75 76–86 87–160
Age, years 75.5 (8.5) 75.0 (8.6) 73.9 (8.8) 71.9 (9.6) <0.0001
Female sex, % 21.8 21.5 26.6 28.6 0.03
Body mass index, kg/m2 27.5 (4.6) 28.0 (4.9) 28.0 (4.8) 28.0 (4.9) 0.37
History of coronary artery disease, % 38.7 33.3 28.4 22.2 <0.0001
History of stroke or TIA, % 22.5 19.5 21.8 17.2 0.21
History of hypertension, % 76.5 76.9 73.2 75.6 0.61
History of heart failure, % 39.5 31.9 33.9 28.6 0.009
History of diabetes, % 21.0 19.2 18.5 18.8 0.81
Smoking status, %
  Current 5.6 6.6 6.3 9.0 0.20
  Former 53.2 50.5 45.8 48.8
  Never 41.3 43.0 47.9 42.3
Oral anticoagulation, % 93.9 92.5 94.7 88.1 0.002
Antiarrhythmic drugs*, %
  Class 1c 1.0 1.1 1.0 2.5 0.20
  Class 2 65.8 74.9 75.2 75.2 0.004
  Class 3 8.1 10.6 11.7 14.3 0.04
  Class 4 27.6 26.0 18.2 18.6 0.001
Use of digoxin, % 9.1 9.1 8.9 7.2 0.69
Regular physical activity, % 42.4 42.5 42.5 43.2 0.99
Alcohol consumption, standard units/day 0.80 (1.4) 0.57 (1.4) 0.43 (1.2) 0.50 (1.1) 0.13
Normally distributed continuous data are presented as means (SD), qualitative data are presented as absolute numbers (percentages). Non- normally 
distributed data (alcohol use) are presented as median (IQR).
*Vaughan William classifications: class 1c, sodium- channel blockers, class 2=beta- blockers, class 3=amiodarone, sotalol and dronedarone; class 
4=non- dihydropyridine calcium- channel blockers.
TIA, transient ischaemic attack.
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(95% CI 11.8 to 17.6) per 1000 person- years. We found no 
evidence of an association between heart rate and stroke 
or systemic embolism, in either Cox or competing risks 
models (tables 2 and 3). The number of events among 
subjects with high heart rates was very small (n=3), and 
associations with stroke were not assessed in this stratum. 
There was no evidence of a nonlinear relationship 
(p=0.30). We found no evidence of interaction between 
sex and heart rate (p for interaction=0.85) or history of 
heart failure and heart rate (p for interaction=0.11).
Heart rate and mortality
There were 283 deaths during follow- up (incidence 
rate 41.4 (95% CI 36.9 to 46.5) per 1000 person- years. 
Heart rate was not associated with mortality, either as a 
continuous variable or among subjects with low or high 
heart rates (table 2), and there was no evidence of a 
nonlinear association (p=0.20). We found no evidence of 
an interaction between heart rate and either sex (p for 
interaction=0.77) or history of heart failure status (p for 
interaction=0.17).
DISCUSSION
In this large cohort of stable outpatients with prevalent 
AF at the time of enrolment, we found no significant 
associations of heart rate with the risks of incident heart 
failure hospitalisation, stroke or systemic embolism and 
death. Most patients had a resting heart rate between 60 
and 100 bpm, likely a reflection of the inclusion of stable 
outpatients in this contemporary cohort, who would have 
received treatment if they had more extreme heart rates. 
There was no evidence of nonlinear associations, and 
neither a heart rate <60 bpm nor a heart rate >100 bpm 
was significantly associated with adverse outcomes.
Table 2 Cox regression models for the associations of resting heart rate with adverse outcomes
Events
Incidence rate, per 
1000 (95% CI)
Model 1 Model 2
HR 95% CI P value HR 95% CI P value
Heart failure hospitalisation 301 47.3 (42.3 to 53.0)
Per 10 bpm increase 0.98 0.92 to 1.05 0.57 1.00 0.94 to 1.07 0.95
<60 bpm 31 52.3 (36.8 to 74.4) 0.97 0.67 to 1.41 0.88 0.92 0.63 to 1.34 0.65
≥100 bpm 33 39.6 (28.2 to 55.8) 1.03 0.72 to 1.49 0.85 1.17 0.81 to 1.70 0.40
Total mortality 283 41.4 (36.9 to 46.5)
Per 10 bpm increase 0.99 0.93 to 1.06 0.82 1.02 0.95 to 1.09 0.66
<60 bpm 30 46.4 (32.8 to 66.4) 0.96 0.65 to 1.40 0.82 0.89 0.60 to 1.31 0.55
≥100 bpm 25 28.3 (19.1 to 41.7) 0.85 0.56 to 1.29 0.45 0.94 0.62 to 1.44 0.79
Stroke or systemic embolism 96 14.4 (11.8 to 17.6)
Per 10 bpm increase 0.93 0.83 to 1.05 0.27 0.95 0.84 to 1.07 0.38
<60 bpm 10 16.0 (8.6 to 29.7) 0.98 0.51 to 1.90 0.95 0.95 0.48 to 1.84 0.87
Model 1 is adjusted for age and sex.
Model 2 is adjusted for model 1+body mass index, physical activity, smoking status (never, former or current), type of AF (paroxysmal and persistent 
vs permanent), alcohol use (log- transformed), history of stroke/TIA, history of heart failure, hypertension, diabetes, the use of beta- blockers, non- 
dihydropyridine calcium- channel blockers, class 1c antiarrhythmic drugs, class 3 antiarrhythmic drugs, digoxin and oral anticoagulation.
AF, atrial fibrillation; TIA, transient ischaemic attack.
Table 3 Competing risks regression analyses for incident heart failure and stroke by heart rate
Model 1 Model 2
SHR 95% CI P value SHR 95% CI P value
Heart failure hospitalisation
Per 10 bpm increase 0.98 0.91 to 1.05 0.54 0.99 0.92 to 1.06 0.78
<60 bpm 0.99 0.68 to 1.44 0.95 0.95 0.65 to 1.39 0.79
≥100 bpm 1.05 0.72 to 1.53 0.79 1.16 0.79 to 1.71 0.44
Stroke or systemic embolism
Per 10 bpm 0.93 0.84 to 1.03 0.17 0.94 0.84 to 1.06 0.30
<60 bpm 1.01 0.52 to 1.93 0.99 0.97 0.49 to 1.90 0.92
Model 1 is adjusted for age and sex.
Model 2 is adjusted for model 1+ body mass index, physical activity, smoking status (never, former or current), type of AF (paroxysmal and persistent 
vs permanent), alcohol use (log- transformed), history of stroke/TIA, history of heart failure, hypertension, diabetes, the use of beta- blockers, non- 
dihydropyridine calcium- channel blockers, class 1c antiarrhythmic drugs, class 3 antiarrhythmic drugs, digoxin and oral anticoagulation.
Includes 1679 subjects, with 162 subjects with heart rate <60 and 201 subjects with heart rate ≥100 bpm.
AF, atrial fibrillation; SHR, sub- HR; TIA, transient ischaemic attack.
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The Early Treatment of Atrial Fibrillation for Stroke 
Prevention Trial (EAST- AFNET) recently found that 
early rhythm control treatment improved adverse clinical 
outcomes in patients with early AF.19 Whether these data 
apply to a wider group of AF patients is currently unclear. 
In addition, in symptomatic patients with uncontrolled 
AF, rate or rhythm control are important to improve 
haemodynamic stability and AF- related symptoms and to 
prevent or reverse systolic dysfunction.3 12 20 However, in 
daily clinical practice, the great majority of elderly patients 
with AF do not complain about AF- related symptoms and 
are haemodynamically stable, despite widely varying heart 
rates, and despite variable use of rate- controlling agents. 
Our data do not apply to the first group of patients, but 
do suggest that in the latter population, more stringent 
heart rate control is not needed for the prevention of 
adverse outcomes. The present study suggests that this 
concept is applicable to a broad group of elderly patients 
with a high prevalence of comorbidities.
In previous studies, there has been some controversy 
regarding the prognostic significance of heart rate. For 
example, a higher heart rate on the baseline ECG was 
associated with incident heart failure in a study where 
patients in AF and sinus rhythm were analysed together.21 
On the other hand, heart rate during AF was not asso-
ciated with all- cause or cardiovascular mortality in a 
pooled analysis of two cohorts, in contrast to heart rate 
during sinus rhythm.8 Similarly, in patients with preva-
lent AF, heart rate was not associated with the composite 
endpoint of death, cardiovascular hospitalisation and 
myocardial infarction after multivariable adjustment.7 
Our study adds to this literature, by confirming that in 
stable contemporary outpatients with prevalent AF, heart 
rate was not associated with adverse outcomes. In addi-
tion, we found no evidence of a threshold effect for heart 
rates <60 bpm or >100 bpm, considered adequate heart 
rate thresholds by current guidelines.22
Our data are in line with the RACE- II trial, where a 
strict rate control strategy (<80 bpm at rest) was not 
superior to a lenient rate control strategy (<110 bpm at 
rest).6 The mean heart rates of our study patients were 
in the same range as in RACE- II, where the mean heart 
rate achieved was 93 bpm and 76 bpm in the lenient and 
strict rate control arm, respectively. While one of the few 
randomised trials in this field, the sample size in RACE- II 
was relatively small, the primary endpoint included 
heterogeneous outcomes, and patients with a history of 
stroke were excluded,6 such that our study may provide 
some reassurance with regard to the generalisability of 
these findings.
Strengths and limitations
Strengths of this analysis include the relatively large 
sample size of contemporary patients with AF, a limited 
amount of missing data and a relatively long and complete 
follow- up. However, there are some potential limitations 
that should be considered when interpreting our data. 
First, as in any observational study, we cannot assess 
causality and residual confounding may persist even 
after extensive multivariable adjustment. Moreover, some 
residual confounding due to change in confounders 
during follow- up may also exist, but given that adjust-
ment for the covariates at baseline had little effect on the 
results, we do not consider that any such confounding 
would have significantly altered these results. Second, 
heart rate thresholds (<60 and ≥100 bpm) were chosen to 
represent commonly used definitions of bradycardia and 
tachycardia. Our study was not sufficiently powered to 
determine whether more extreme heart rates are signif-
icantly associated with adverse outcome events. In addi-
tion, many AF patients with more extreme heart rates are 
symptomatic and require interventions anyway. Third, the 
heart rate was derived from one 10 s ECG strip at baseline. 
While this is the current clinical standard in most stable 
patients with AF, it is possible that a more detailed assess-
ment of the heart rate using longer recording times (eg, 
24- hour Holter recording) may provide different associ-
ations with clinical outcomes in this population. It is also 
possible that related parameters such as heart rate varia-
bility may improve risk stratification, and further studies 
are needed in this area. Nevertheless, current clinical 
practice still heavily relies on short heart rate assessments.
CONCLUSIONS
In conclusion, in this large cohort of patients with prev-
alent AF, heart rate was not associated with heart failure 
hospitalisation, stroke or systemic embolism and death. 
These data are in line with recommendations that strict 
heart rate control is not needed in most stable outpa-
tients with AF.
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